OCUL (Ocular Therapeutix, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by OCUL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Donald Notman | Chief Operating Officer | Sell | — | — |
| 2026-08-26 | Pravin Dugel | See Remarks | MIXED | — | — |
| 2026-08-26 | Peter Kaiser | Chief Development Officer | Sell | — | — |
| 2026-08-26 | Jeffrey S. Heier | Chief Scientific Officer | Sell | — | — |
| 2026-08-26 | Sanjay Nayak | Chief Strategy Officer | Sell | — | — |
| 2026-06-18 | Pravin Dugel | See Remarks | G | — | — |
| 2026-06-12 | Adrienne L Graves | Director | A | — | — |
| 2026-06-12 | Jason Shand Robins | Chief Financial Officer | A | — | — |
| 2026-06-12 | MERILEE RAINES | Director | A | — | — |
| 2026-06-12 | Charles M Warden | Director | A | — | — |
| 2026-06-12 | Seung Suh Hong | Director | A | — | — |
| 2026-06-12 | RICHARD L MD LINDSTROM | Director | A | — | — |
| 2026-06-12 | Leslie J. Williams | Director | A | — | — |
| 2026-06-05 | Nadia Waheed | Chief Medical Officer | Sell | — | — |
| 2026-05-28 | Sanjay Nayak | Chief Strategy Officer | Sell | — | — |
| 2026-05-28 | Jeffrey S. Heier | Chief Scientific Officer | Sell | — | — |
| 2026-05-28 | Peter Kaiser | Chief Development Officer | Sell | — | — |
| 2026-05-28 | Pravin Dugel | See Remarks | MIXED | — | — |
| 2026-04-13 | Pravin Dugel | See Remarks | G | — | — |
| 2026-02-25 | Jeffrey S. Heier | Chief Scientific Officer | Sell | — | — |
| 2026-02-25 | Peter Kaiser | Chief Development Officer | Sell | — | — |
| 2026-02-25 | Sanjay Nayak | Chief Strategy Officer | Sell | — | — |
| 2026-02-25 | Pravin Dugel | See Remarks | Sell | — | — |
| 2026-02-24 | Nadia Waheed | Chief Medical Officer | Sell | — | — |
| 2026-02-24 | RICHARD L MD LINDSTROM | Director | Buy | — | — |
| 2026-02-17 | Nadia Waheed | Chief Medical Officer | Sell | — | — |
| 2026-02-17 | Sanjay Nayak | Chief Strategy Officer | Sell | — | — |
| 2026-02-17 | Donald Notman | Chief Operating Officer | Sell | — | — |
| 2026-02-17 | Pravin Dugel | See Remarks | Sell | — | — |
| 2026-02-04 | Donald Notman | Chief Operating Officer | Sell | — | — |
| 2026-01-26 | David Wayne Robinson | Global CCO | A | — | — |
| 2026-01-22 | Jason Shand Robins | Interim CFO | A | — | — |
| 2026-01-06 | Sanjay Nayak | Chief Strategy Officer | A | — | — |
| 2026-01-06 | Peter Kaiser | Chief Development Officer | A | — | — |
| 2026-01-06 | Namrata Saroj | Chief Business Officer | A | — | — |
| 2026-01-06 | Jeffrey S. Heier | Chief Scientific Officer | A | — | — |
| 2026-01-06 | Donald Notman | See Remarks | A | — | — |
| 2026-01-06 | Nadia Waheed | Chief Medical Officer | A | — | — |
| 2026-01-06 | Steve Lawrence Meyers | Chief Commercial Officer | A | — | — |
| 2026-01-06 | Todd Anderman | Chief Legal Officer | A | — | — |
| 2025-11-26 | Sanjay Nayak | Chief Strategy Officer | Sell | — | — |
| 2025-11-26 | Peter Kaiser | Chief Development Officer | Sell | — | — |
| 2025-11-26 | Pravin Dugel | See Remarks | MIXED | — | — |
| 2025-11-26 | Jeffrey S. Heier | Chief Scientific Officer | Sell | — | — |
| 2025-11-07 | Namrata Saroj | Chief Business Officer | Sell | — | — |
| 2025-10-10 | Todd Anderman | Chief Legal Officer | Sell | — | — |
| 2025-10-06 | Jeffrey S. Heier | Chief Scientific Officer | Sell | — | — |
| 2025-10-06 | Peter Kaiser | Chief Development Officer | Sell | — | — |
| 2025-09-11 | Pravin Dugel | See Remarks | G | — | — |
| 2025-09-04 | Donald Notman | See Remarks | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,591,401 | — |
| — | 10%+ Owner | 4,364,130 | — |
| — | See Remarks | 3,270,332 | — |
| — | 10%+ Owner | 2,215,384 | — |
| — | 10%+ Owner | 1,958,824 | — |
| — | 10%+ Owner | 1,693,767 | — |
| — | Chairman of the Board | 1,435,450 | — |
| — | President and CEO | 595,201 | — |
| — | Director | 475,585 | — |
| — | Chief Operating Officer | 366,356 | — |
| — | Chief Strategy Officer | 326,898 | — |
| — | Chief Scientific Officer | 318,326 | — |
| — | President, Ophthalmology & CMO | 313,335 | — |
| — | Director | 304,492 | — |
| — | Chief Medical Officer | 300,079 | — |
| — | Chief Development Officer | 264,378 | — |
| — | Chief Business Officer | 254,620 | — |
| — | Chief Commercial Officer | 217,628 | — |
| — | 10%+ Owner | 207,500 | — |
| — | General Counsel | 161,493 | — |
| — | Chief Medical Officer | 153,054 | — |
| — | Chief Legal Officer | 152,468 | — |
| — | Global CCO | 136,000 | — |
| — | Director | 130,448 | — |
| — | Chief Business Officer | 123,689 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OCUL quote page; the site-wide leaderboard is on the insider transactions hub.